3 months ago
PVLA
AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Industries:
Analyst Ranking
Top 15%
#738 out of 5206 analysts
Average Return
+60.05%
Win Rate
75%15 out of 20
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inozyme Pharma IncINZY | +270.37% | $1.08 | $4.00 | 2025-03-12 - 2025-07-01 | Buy |
Palvella Therapeutics IncPVLA | +239.42% | $39.07 | $132.61 | 2025-08-06 - 2026-03-02 | Buy |
Liquidia CorpLQDA | +183.15% | $9.79 | $27.72 | 2024-08-19 - 2025-08-18 | Strong Buy |
Trevi Therapeutics IncTRVI | +129.59% | $3.16 | $7.26 | 2024-08-30 - 2025-08-29 | Buy |
Trevi Therapeutics IncTRVI | +107.08% | $6.07 | $12.57 | 2025-03-10 - 2026-03-02 | Strong Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | 2 | Strong Buy | $143.00 | +7.84% | Upgrades | 3 months ago |
Liquidia CorpLQDA | 4 | Strong Buy | $41.00 | +32.51% | Maintains | 7 months ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $27.00 | +114.80% | Maintains | 7 months ago |
Ardelyx IncARDX | 2 | Buy | $12.00 | +85.47% | Maintains | 7 months ago |
Apellis Pharmaceuticals IncAPLS | 2 | Buy | $50.00 | +141.55% | Maintains | 7 months ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $122.00 | +265.93% | Maintains | 7 months ago |
Tvardi Therapeutics IncTVRD | 1 | Buy | $62.00 | +1,465.66% | Initiates Coverage On | 8 months ago |
Inozyme Pharma IncINZY | 2 | Hold | $4.00 | 0.00% | Downgrades | 10 months ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | N/A | Maintains | a year ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.